Organogenesis (ORGO) Competitors

Organogenesis (NASDAQ:ORGO) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.

Do analysts recommend ORGO or EVO?

Organogenesis currently has a consensus price target of $5.50, suggesting a potential upside of 74.33%. Evotec has a consensus price target of $5.93, suggesting a potential upside of 47.23%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts plainly believe Organogenesis is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Evotec	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Which has stronger earnings & valuation, ORGO or EVO?

Organogenesis has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$458.76M	0.87	$4.95M	-$0.17	-18.56
Evotec	$788.22M	1.82	-$90.82M	N/A	N/A

Does the media prefer ORGO or EVO?

In the previous week, Organogenesis had 5 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Organogenesis and 1 mentions for Evotec. Organogenesis' average media sentiment score of 1.62 beat Evotec's score of 1.20 indicating that Organogenesis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Evotec	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in ORGO or EVO?

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 36.9% of Organogenesis shares are owned by insiders. Comparatively, 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer ORGO or EVO?

Organogenesis received 90 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 65.99% of users gave Organogenesis an outperform vote while only 53.85% of users gave Evotec an outperform vote.

Company	Underperform	Outperform
Organogenesis	Outperform Votes 97 65.99%	Underperform Votes 50 34.01%
Evotec	Outperform Votes 7 53.85%	Underperform Votes 6 46.15%

Which has more volatility and risk, ORGO or EVO?

Organogenesis has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

Is ORGO or EVO more profitable?

Evotec has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Evotec's return on equity of 0.00% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-1.62%	-2.69%	-1.63%
Evotec	N/A	N/A	N/A

Summary

Organogenesis beats Evotec on 10 of the 16 factors compared between the two stocks.